Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage biotechnology company focused on developing gene therapies for prevalent ocular diseases. Leveraging its proprietary intravitreal platform, Adverum aims to deliver durable, single-administration treatments that eliminate the need for frequent injections. The company's lead candidate, ixoberogene soroparvovec (Ixo-vec), targets neovascular and wet age-related macular degeneration with the goal of restoring vision and preventing blindness.
Adverum Biotechnologies, Inc. is a clinical-stage company developing gene therapy for ocular diseases. They are looking for a Research Associate II or III (contract) to join their team in Redwood City, CA.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage biotechnology company focused on developing gene therapies for prevalent ocular diseases. Leveraging its proprietary intravitreal platform, Adverum aims to deliver durable, single-administration treatments that eliminate the need for frequent injections. The company's lead candidate, ixoberogene soroparvovec (Ixo-vec), targets neovascular and wet age-related macular degeneration with the goal of restoring vision and preventing blindness.
Adverum Biotechnologies, Inc.